Brofaromine
From Wikipedia, the free encyclopedia
 |
|
|
Brofaromine
|
|
| Systematic (IUPAC) name | |
| 4-(7-bromo-5-methoxy-1-benzofuran-2-yl)piperidine | |
| Identifiers | |
| CAS number | |
| ATC code | ? |
| PubChem | |
| Chemical data | |
| Formula | C14H16BrNO2 |
| Mol. mass | 310.186 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Protein binding | 98% |
| Metabolism | ? |
| Half life | 9 to 14 hours |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | Oral |
Brofaromine is a reversible inhibitor of monoamine oxidase A primarily useful in the treatment of depression and anxiety. It is not commercially available and is not being actively researched, possibly due to a lack of financial interest.[1]
[edit] Pharmacology
Brofaromine is a reversible inhibitor of monoamine oxidase A (RIMA, a type of monoamine oxidase inhibitor (MAOI)) and acts on epinephrine (adrenaline), norepinephrine (noradrenaline), serotonin, and dopamine. Unlike standard MAOIs, possible side effects do not include cardiovascular complications (hypertension) with encephalopathy, liver toxicity or hyperthermia.
[edit] References
- ^ Lotufo-Neto F, Trivedi M, Thase ME (1999). "Meta-analysis of the reversible inhibitors of monoamine oxidase type A moclobemide and brofaromine for the treatment of depression". Neuropsychopharmacology 20 (3): 226–47. doi:. PMID 10063483. Free full text
|
|||||||||||||||||||||||||||||||
 |
This psychoactive drug-related article is a stub. You can help Wikipedia by expanding it. |
